Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mirna Therapeutics Presents Preclinical Data on Lead Product Candidate

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
Mirna Therapeutics, Inc. announced that new preclinical data from its lead product candidate will be presented this week at the Keystone conference on Non-coding RNAs in Development and Cancer.

New data will be presented on the pharmacology, pharmacokinetics and toxicology of MRX34, a liposomal formulation containing a mimic of the miR-34 tumor suppressor. miR-34 represses the expression of more than 20 oncogenes and inhibits processes required for cancer cell viability, cancer stemness, metastasis, and chemoresistance. The company has previously demonstrated that intravenous administration of the miR-34 mimic can inhibit the growth of pre-existing B-cell lymphoma, liver, lung and prostate cancer (Craig et al., 2012; Wiggins et al., 2010, Trang et al., 2011, Liu et al., 2011).

MRX34 was well tolerated in rodents and non-human primates during IND-enabling studies and did not induce RNAi-mediated toll-like receptor activation or immune response at anticipated therapeutic dose levels. The pharmacokinetic profiles suggest a satisfactory residence time in blood and will be used to determine the recommended human starting dose and treatment regimen in the clinic.

“These data continue to support the safety profile and therapeutic potential of MRX34. We are on track to file an Investigational New Drug application (IND) for MRX34 with the US Food and Drug Administration and initiate clinical testing of this miRNA replacement therapy approach in the first half of this year in patients diagnosed with primary liver cancer or advanced solid cancers with liver involvement,” said Paul Lammers, M.D., President and Chief Executive Officer of Mirna Therapeutics.

This project was funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Commercialization grant.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mirna Therapeutics and Horizon Discovery Uncover Important Tumor Suppressor Pathway
Paper reports new findings on tumor suppressor miR-34 relationship with p53 and p21 cancer pathways.
Thursday, June 27, 2013
Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer
Phase 1 clinical trial of anticancer drug MRX34 underway.
Tuesday, May 14, 2013
Scientific News
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!